RRG001

RRG001 gene therapy · Shanghai Refreshgene Technology Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for RRG001, covering 2024-05-14 to 2024-11-14. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) [Phase 1, Phase 2]

See pricing